Company
Takeda
2 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.
Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.
Biomarkers
Drugs in these trials
Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).
Upcoming readouts
Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.
- 2026-10 A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer Phase 1/2 · EGFR exon 19 deletion / L858R, EGFR exon 20 insertion, HER2 (ERBB2) activating mutation
Trials
2 of 17 trials shown
-
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
…one of the following documented by a local test: an activating mutation in EGFR including exon 19 deletions or exon 21 L858R substitution (with or without T790M), or an uncommon activating mutatio…
EGFR exon 19 deletion / L858REGFR exon 20 insertionHER2 (ERBB2) activating mutationCarcinoma, Non-Small-Cell Lung
-
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
A documented EGFR in-frame exon 20 insertion (including A763\_Y764insFQEA, V769\_D770insASV, D770\_N771insNPG, D770\_N771insSVD, H773\…
EGFR exon 20 insertionNon-Small Cell Lung Cancer
-
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
mobocertinibpemetrexedcisplatincarboplatin
…mutations for which there are approved anti-EGFR tyrosine kinase inhibitors \[TKIs\] (ie, exon 19 del, L858R, T790M, L861Q, G719X, or S768I, where X is any other amino acid)
EGFR exon 19 deletion / L858REGFR exon 20 insertionHER2 (ERBB2) activating mutationAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
-
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
brigatinib FDA EUalectinib FDA EU
Have documentation of ALK rearrangement by a positive result from the Vysis ALK Break-Apart fluorescence in situ hybridization (F…
ALK fusionALK+ Advanced NSCLC
-
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
brigatinib FDA EUcrizotinib FDA EU
Must have documented ALK rearrangement.
ALK fusionNon-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
-
A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788
mobocertinibAntidiarrheal prophylaxis
A documented epidermal growth factor receptor (EGFR) mutation with in-frame exon 20 insertion, confirmed as follows:
EGFR exon 19 deletion / L858REGFR exon 20 insertionNon-Small Cell Lung Cancer (NSCLC)
-
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
TAK-981pembrolizumab
…aberrations (e.g., epidermal growth factor receptor (EGFR), B-Raf proto-oncogene mutation V600E \[BRAF V600E\], and ROS proto-oncogene 1 \[ROS1\] sensitizing mutations, neurotrophic rec…
BRAF V600EAdvanced or Metastatic Solid Tumors
-
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
brigatinib FDA EU
Participants are required to provide prior results showing an activating ALK aberration in the tumor (bone marrow aspirate, peripheral blood samples, biopsy, etc) documented by …
ALK fusionAnaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors
-
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Dazostinagpembrolizumab FDA EUPlatinumfluorouracil
Third-line or later MSI-H/dMMR CRC (Part 3A): Participants with histologically confirmed (cytological diagnosis is …
MSI-H / dMMRSolid Neoplasms
-
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
brigatinib FDA EU
Have documentation of anaplastic lymphoma kinase (ALK) rearrangement by a positive result from any laboratory test® approved by the food and drug administrati…
ALK fusionALK-positive Advanced NSCLC
-
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
TAK-981
…ations (example- epidermal growth factor receptor \[EGFR\], B-Raf proto-oncogene mutation V600E \[BRAF V600E\], and ROS proto-oncogene 1 \[ROS1\] sensitizing mutations, neurotrophic rec…
BRAF V600ENeoplasms, Lymphoma, Hematologic Neoplasms
-
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
niraparib FDA EU
…or (defined by the presence of a deleterious or suspected deleterious breast cancer gene (BRCA) mutation or be positive for genomic instability) by the central laboratory selected by the sponsor…
BRCA1/2 mutationOvarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
-
Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
brigatinib FDA EU
Have documentation of ALK rearrangement that meets following criteria.
ALK fusionALK-positive Advanced NSCLC
-
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
brigatinib FDA EU
…nced or metastatic Non-small Cell Lung Cancer (NSCLC) that is anaplastic lymphoma kinase (ALK+).
ALK fusionCarcinoma, Non-Small-Cell Lung
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
brigatinib FDA EU
…ll cell lung cancer (NSCLC) participants whose tumors exhibit anaplastic lymphoma kinase (ALK) rearrangements and who have not been treated with previous ALK inhibitors.
ALK fusionROS1 fusionLymphoma, Large-Cell, Anaplastic, Carcinoma, Non-Small-Cell Lung
-
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
midazolambrigatinib FDA EU
With locally advanced or metastatic ALK-positive NSCLC who have progressed on or are intolerant to treatment with at least 1 other ALK inh…
ALK fusionROS1 fusionCarcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
-
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
tovorafenib FDA EUTAK-202vedolizumabnivolumabipilimumab
a) BRAF V600 mutation-positive or NRAS mutation-positive disease previously untreated with RAF, MEK, o…
BRAF V600EMelanoma
No trials match these filters.